Advertisement
Advertisement
RIGL
Rigel Pharmaceuticals Inc. (New)
26.04
USDSponsored
-0.20
-0.76%
May 08, 15:59 UTC -4
Closed
Pre-Market
28.37
+2.33
+8.94%
RIGL Earnings Reports
Positive Surprise Ratio
RIGL beat 30 of 42 last estimates.
71%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$70.90M
/$1.06
Implied change from Q1 26 (Revenue/ EPS)
+20.54%
/+140.91%
Implied change from Q2 25 (Revenue/ EPS)
-30.27%
/-67.68%
Rigel Pharmaceuticals Inc. (New) earnings per share and revenue
On May 05, 2026, RIGL reported earnings of 0.44 USD per share (EPS) for Q1 26, missing the estimate of 0.69 USD, resulting in a -36.87% surprise. Revenue reached 58.82 million, compared to an expected 63.64 million, with a -7.57% difference. The market reacted with a -5.06% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of 1.06 USD, with revenue projected to reach 70.90 million USD, implying an increase of 140.91% EPS, and increase of 20.54% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Rigel Pharmaceuticals Inc. (New)'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Rigel Pharmaceuticals Inc. (New) reported EPS of $0.44, missing estimates by -36.87%, and revenue of $58.82M, -7.57% below expectations.
How did the market react to Rigel Pharmaceuticals Inc. (New)'s Q1 2026 earnings?
The stock price moved down -5.06%, changed from $28.09 before the earnings release to $26.67 the day after.
When is Rigel Pharmaceuticals Inc. (New) expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Rigel Pharmaceuticals Inc. (New)'s next earnings report?
Based on 4
analysts, Rigel Pharmaceuticals Inc. (New) is expected to report EPS of $1.06 and revenue of $70.90M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement